Can monoclonal antibodies fight antimicrobial resistance? Yes! Scientists believe they could be the answer to superbugs like ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m. Eastern Time on Thurs6, 2024. Chief Business ...
Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has approved Zenrelia™, a safe, highly effective, and convenient once-daily oral JAK ...
Responding to the skyrocketing need for short-term, affordable behavioral health care among children and young adults, Altior Healthcare today announced that it has completed the conversion of two ...
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference on Thursday, Sept ...
Amlan International, a leading innovator in mineral-based feed additives for poultry and animal production, is pleased to announce the appointment of Marty Thompson as Southwest Key Accounts Manager ...
PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...
Fast Track Designation is available to drugs that may provide an advantage over current therapies in the treatment of serious conditions. It is designed to speed the development o ...
CS Genetics, an innovative genomics technology company, today announced a strategic partnership with ROSALIND®, the premier SaaS platform empowering life science research across diverse technologies.
The new entity, operational under the name MogulBodyCare, LLC, brings together the current offerings of both organizations and enables greater access to weight loss medications, i ...
Navident EVO will apply its dynamic navigation technology to provide minimally invasive access to tooth structures requiring endodontic treatment. The dual advantage of preserving ...
Mantle Cell Lymphoma Pipeline Report Introduction 2. Mantle Cell Lymphoma Pipeline Report Executive Summary 3. Mantle ...